This study will determine the efficacy of etanercept in children with systemically active systemic onset juvenile rheumatoid arthritis (SOJRA).
Phase 3 Safety and Efficacy Study of Etanercept (Enbrel®) In Children with Systemic Onset Juvenile Rheumatoid Arthritis
Arthritis, Juvenile Rheumatoid
Treatment, Placebo Control, Safety/Efficacy Study
Eligibility & Criteria
Ages Eligible for Study: 2 Years – 18 Years, Genders Eligible for Study: Both Criteria – Patients must have systemic features of SOJRA – Active joints – Abnormal labs; albumin, platelets, Hgb, CRP – Stable dose of Prednisone – Stable dose or Off Methotrexate for 4 weeks – Blinded, placebo controlled
For additional information regarding investigative sites for this trial, contact the Amgen Call Center at 1-866-57AMGEN (1-866-572-6436)
All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.